Disease Domain | Count |
---|---|
Neoplasms | 3 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Target |
Mechanism CDK4 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Feb 2021 |
Target |
Mechanism CDK4 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ERs antagonists |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Jan 2024 |
Sponsor / Collaborator |
Start Date18 Oct 2023 |
Sponsor / Collaborator |
Start Date12 Oct 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Trilaciclib Dihydrochloride ( CDK4 x CDK6 ) | Chemotherapy-induced myelosuppression More | Approved |
Lerociclib ( CDK4 x CDK6 ) | Hormone receptor positive HER2 negative breast cancer More | NDA/BLA |
Rintodestrant ( ER ) | Breast Cancer More | Phase 2 |
G1T30-1 ( CDK4 x CDK6 ) | Neoplasms More | Pending |
G1T-4x | Neoplasms More | Pending |